eIF3亚家族与恶性肿瘤发生的关系

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (10): 1195-1200.

• 综述与讲座 • 上一篇

eIF3亚家族与恶性肿瘤发生的关系

韩丽芳, 刘昭前

中南大学临床药理研究所, 遗传药理学湖南省重点实验室, 长沙 410078, 湖南

收稿日期:2008-09-03 修回日期:2008-09-26 出版日期:2008-10-26 发布日期:2020-10-19
通讯作者: 刘昭前,男, 博士, 教授, 博士生导师, 研究方向:遗传药理学和临床药理学。Tel:0731-4805380
作者简介:韩丽芳, 女, 硕士研究生, 研究方向:遗传药理学。Tel:0731-4805380 　 E-mail:hanlifang588@163.com
基金资助:
国家自然科学基金项目(30572230); 湖南省自然科学基金重点项目(08JJ3058); 湖南省“芙蓉学者计划” 特聘教授基金(湘教通[2006] 312 号)

Relationship between eIF3 subfamily and the development of tumor

HAN Li-fang, LIU Zhao-qian

Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University Xiangya School of Medicine, Changsha 410078, Hunan, China

Received:2008-09-03 Revised:2008-09-26 Online:2008-10-26 Published:2020-10-19

摘要/Abstract

摘要： eIF3 是相对分子质量最大和最复杂的一个真核细胞翻译起始因子,它在真核细胞翻译调控中发挥非常重要的作用。最近研究发现, eIF3 的许多亚基在人类肿瘤中表达量发生改变, 从而影响肿瘤的发生、发展和预后。本文主要对 eIF3 亚家族与肿瘤发生的关系进行综述。

关键词: eIF3, 翻译起始因子, 肿瘤

Abstract: eIF3 is the largest and most complex eukaryotic initiation factor in mammals, and it plays an important role in the regulation of translation .Some studies showed that the changes of levels of gene and protein expression of many subunits in eIF3 family are associated with the development, progression, and prognosis of human tumors. The relationship between eIF3 subfamily and the tumor development and progres-sion was reviewed in this article.

Key words: elF3, eukaryotic initiation factors, tu-mor

中图分类号:

R730

韩丽芳, 刘昭前. eIF3亚家族与恶性肿瘤发生的关系[J]. 中国临床药理学与治疗学, 2008, 13(10): 1195-1200.

HAN Li-fang, LIU Zhao-qian. Relationship between eIF3 subfamily and the development of tumor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1195-1200.

参考文献

[1] De Benedetti A, Harris AL. elF4E expression in tumors:its possible role in progression of malignancies[J] .Int J Bio-chem Cell Biol, 1999, 31(1) :59-72.
[2] Browning KS, Gallie DR, Hershey JW, et al.Unified no-menclature for the subunits of eukaryotic initiation factor 3[J] .Trends Biochem Sci, 2001, 26(5) :284.
[3] BachmannF, Banziger R, Burger MM. Cloning of a novel protein overexpressed in human mammary carcinoma[J] . Cancer Res, 1997, 57(5) :988-994.
[4] Dellas A, Torhorst J, Bachmann F, et al.Expression of p150 in cervical neoplasia and its potential value in pre-dicting survival[J] .Cancer, 1998, 83(7) :1376-1383.
[5] Chen G, Burger MM. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus[J] . Cancer, 1999, 84(2) :95-100.
[6] Lin L, Holbro T,Alonso G, et al. Molecular interaction be-tween humaltumor marker protein p150, the largest subunit of elF3, and in termediate filament protein K7[J] .J Cell Biochem, 2001, 80(4) :483-490.
[7] Chen G, Burger MM. p150 overexpression in gastric car-cinoma:the association with p53, apoptosis and cell pro-liferation[J] .Int J Cancer, 2004, 112(3) :393-398.
[8] Dong ZZ, Liu LH, Han BG, et al.Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth[J] .Oncogene, 2004, 23(21) :3790-3801.
[9] Zhang L, Pan X, Hershey JW.Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells[J] .J Biol Chem, 2007, 282(8) :5790-800.
[10] Dong Z, Zhang JT.EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression[J] . Mol Biol Cell, 2003, 14(9) :3942-3951.
[11] 沈杰, 李慧华, 张建亭, 等.eIF3S10在肺癌组织中的表达及与化疗反应的关系[J].国际病理科学与临床杂志, 2006, 26(5) :369-371.
[12] Marchetti A, Buttitta F, MiyazakiS, et al. Int -6, a high-ly conserved, widely expressedgene, is mutated by mouse mammary tumor virus in mammary preneoplasia[J] .JVir-ol, 1995, 69(3) :1932-1938.
[13] Rasmussen SB, Kordon E, Callahan R, et al.Evidence for the transforming activity of a truncated Int6 gene, in vitro[J] .Oncogene, 2001, 20(38) :5291-5301.
[14] Mayeur GL, Hershey JW.Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e)[J] .FEBS Lett, 2002, 514(1) :49-54.
[15] Marchetti A, Buttitta F, Pellegrini S, et al.Reduced ex-pression of INT-6 eIF3-p48 in human tumors[J] .Int J Oncol, 2001, 18(1) :175-179.
[16] Traicoff JL, Chung JY, Braunschweig T, et al.Expres-sion of EIF3-p48 INT6, TID1 and Patched in cancer, a profiling of multiple tumor types and correlation of expres-sion[J] .Journalof BiomedicalScience, 2007, 14(3) :395-405.
[17] Buttitta F, Martella C, Barassi F, et al.Int6 expression can predict survival inearly-stage non-small cell lung can-cer patients[J] .Clin Cancer Res, 2005, 11(9) :3198-204.
[18] Watkins SJ, Norbury CJ.Cell cycle-related variation in subcellular localization of eIF3e INT6 in human fibro-blasts.Cell Prolif, 2004, 37(2) :149-160.
[19] Jenkins CC, Mata J, Crane RF, et al.Activation of AP-1-dependent transcription by a truncated translation initia-tion factor[J] .Eukaryot Cell, 2005, 4(11) :1840-50.
[20] Shi J, Kahle A, Hershey JW, et al.Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells[J] .Oncogene, 2006, 25(35) : 4923-4936.
[21] Doldan A, Chandramouli A, Shanas R, et al.Loss of the eukaryotic initiation factor 3f inpancreatic cancer[J] .Mol Carcinog, 2008, 47(3) :235-244.
[22] Adriana Doldan, Anupama Chandramouli, Reneé Shanas, et al.Loss of the eukaryotic initiation factor 3f in pancreat-ic cancer[J] .Mol Carcinog, 2008, 47(3) :235-344.
[23] Shi J, Feng Y, Goulet AC, et al.The p34cdc2-related cyclindependent kinase 11interactswith the p47 subunitof eukaryotic initiation factor 3 during apoptosis[J] .J Biol Chem, 2003, 278(7) :5062-5071.
[24] Nupponen NN, Porkka K, Kakkola L, et al.Amplifica-tion and overexpression of p40 subunit of eukaryotic trans-lation initiation factor 3 in breast and prostate cancer[J] . Am J Pathol, 1999, 154(6) :1777-1783.
[25] SavinainenKJ, Linja MJ, Saramaki OR, et al. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer[J] .Br J Cancer, 2004, 90(5) :1041-1046.
[26] Saramaki O, Willi N, Bratt O, et al.Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer[J] .Am J Pathol, 2001, 159(6) :2089-2094.
[27] Okamoto H, Yasui K, Zhao C, et al.PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 andare as-sociatedwith large hepatocellular carcinomas[J].Hepatol-ogy, 2003, 38(5) :1242-1249.
[28] Tomlinson IP, Webb E, Carvajal-Carmona L, et al.A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes10p14 and 8q23.3[J] . Nat Genet, 2008, 40(5) :623-630.
[29] Zhang L, Smit -McBride Z, Pan X, et al. An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3[J] .J Biol Chem, 2008, Jun 10. [Epub ahead of print]
[30] Joseph P, Lei YX, Whong WZ, et al.Molecular cloning and functional analysis of a novel cadmium -responsive proto-oncogene[J] .Cancer Res, 2002, 62(3) :703-707.
[31] Lei YX, Joseph P, Ong TM.Antisense inhibition of trans-lation initiation factor 3 reverses its oncogenic potential[J] .Teratog Carcinog Mutagen, 2002, 22(6) :403-409.
[32] Joseph P, Lei YX, Ong TM.Up-regulation of expression of translation factors-a novelmolecular mechanism for cad-mium carcinogenesis[J] .Mol Cell Biochem, 2004, 255(1 -2) :93-101.
[33] Matsuda S, Katsumata R, Okuda T, et al.Molecular cloning and characterization of human MAWD, a novel protein containing WD-40 repeats frequently overexpressed in breast cancer[J] .Cancer Res, 2000, 60(1) :13-17.
[34] Ahlemann M, Zeidler R, Lang S, et al.Carcinoma-asso-ciated eIF3i overexpression facilitates mTOR-dependent growth transformation[J] .Mol Carcinog, 2006, 45(12) : 957-967.
[35] Huang JS, Chao CC, SuTL, et al. Diverse cellular trans-formation capability of overexpressed genes in human hep-atocellular carcinoma[J] .Biochem Biophys Res Commun, 2004, 315(4) :950-958.
[36] Choy L, Derynck R.The type II transforming growth fac-tor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response[J] .J Biol Chem, 1998, 273(47) :31455-31462.
[37] Lin L, Holbro T, Alonso G, et al.Molecular interaction between human tumor marker protein p150, the largest subunit of eIF3, and intermediate filament protein K7[J] . J Cell Biochem, 2001, 80(4) :483-490.
[38] Rothe M, Ko Y, Albers P, et al.Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular semi-nomas[J] .Am J Pathol, 2000, 157(5) :1597-1604.
[39] Scoles DR, Yong WH, Qin Y, et al.Schwannomin inhib-its tumorigenesis through direct interactionwith the eukary-otic initiation factor subunit c (eIF3c)[J] .Human Molec-ular Genetics, 2006, 15(7) :1059-1070.

eIF3亚家族与恶性肿瘤发生的关系

Relationship between eIF3 subfamily and the development of tumor

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[2]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[3]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[4]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[5]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[6]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[7]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[8]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[9]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[10]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[11]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[12]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[13]	洪子强, 苟文曦, 崔百强, 白向豆, 金大成, 苟云久. m7G甲基转移酶METTL1在肿瘤中的作用[J]. 中国临床药理学与治疗学, 2023, 28(1): 93-100.
[14]	缪亚东, 李蹊, 王燕, 高坡, 周敏, 于浩. 抗肿瘤药物临床试验数据管理的一般考虑[J]. 中国临床药理学与治疗学, 2022, 27(9): 1055-1060.
[15]	王亚丽, 霍续磊, 陈峰, 李生兰, 郑晓红, 王灿, 李文斌. 硝呋莫司抗肿瘤作用的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 955-960.